Drug profile · INN
haemophilus b conjugate (meningococcal protein conjugate) and hepatitis b (recombinant) vaccine
PROCOMVAX
haemophilus b conjugate (meningococcal protein conjugate) and hepatitis b (recombinant) vaccine (PROCOMVAX) is a surface antigen (hbsag) vaccine antigen.
Drug details — haemophilus b conjugate (meningococcal protein conjugate) and hepatitis b (recombinant) vaccine
- Class
- Antiinfectives for systemic use (J07)
- Route
- —
- Patents
- 1
- Programs
- 4
- Data quality
- 0.83
Quick answer
haemophilus b conjugate (meningococcal protein conjugate) and hepatitis b (recombinant) vaccine (PROCOMVAX) is a surface antigen (hbsag) vaccine antigen.
Key facts
Mechanism of action
Surface antigen (HBsAg) vaccine antigen
Primary target: Surface antigen (HBsAg)
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | unknown | — |
Pipeline programs
Related & competitor drugs
Related patents
Frequently asked questions
What is haemophilus b conjugate (meningococcal protein conjugate) and hepatitis b (recombinant) vaccine?
haemophilus b conjugate (meningococcal protein conjugate) and hepatitis b (recombinant) vaccine (PROCOMVAX) is a surface antigen (hbsag) vaccine antigen.
What is the brand name for haemophilus b conjugate (meningococcal protein conjugate) and hepatitis b (recombinant) vaccine?
PROCOMVAX is a marketed brand name for haemophilus b conjugate (meningococcal protein conjugate) and hepatitis b (recombinant) vaccine. Check FDA Drugs@FDA for the current US label holder and prescribing information.